Advances in Nuclear Medicine and Molecular Imaging
| Overview / Abstract: |
Advances in Nuclear Medicine and Molecular Imaging features fourteen internationally renowned faculty experts discussing nuclear medicine’s latest trends and emerging procedures. Created from the Mid-Eastern Chapter of the Society of Nuclear Medicine and Molecular Imaging’s 52nd Annual Conference, this activity presents the impact of radiopharmaceuticals on imaging, cardiology, oncology and much more. Robust discussions of imaging tools, administration equipment, dosimetry and future applications are included, as well. Worth 15 AMA PRA Category 1 Credit(s)™, Advances in Nuclear Medicine and Molecular Imaging meets Nuclear Medicine/PET accreditation requirements and provides an essential update for all physicians and technologists involved with this area of medicine. Topics include: Cardiac applications, myocardial imaging, dosimetry, theranostics, radiotracer based bone scanning, lymphoma staging, PET applications for glioblastoma, thyroid cancer and prostate cancer, SPECT-CT, radiation safety, artificial intelligence, emerging radiopharmaceuticals and much more. Available now in online streaming and USB Flash Drive formats! |
|
Expiration |
Oct 03, 2027 |
|
Discipline(s) |
Physician CME, Radiology / RAD Tech CE |
|
Format |
Online |
|
Cost |
595 |
|
Credits / Hours |
15 AMA PRA Category 1 Credit(s)™ |
|
Accreditation |
Global Education Group |
|
Presenters / Authors / Faculty |
Course Director: Michael Morris, M.D. Faculty includes 14 acclaimed experts from the Mid Eastern Chapter of the Society of Nuclear Medicine and Molecular Imaging |
|
Keywords / Search Terms |
Meetings By Mail® Meetings By Mail, MBM, Nuclear Medicine, PET, Molecular Imaging, IAC, PET, CT, MOC, ACR, Nuclear, Morris, Savarese, SNMMI, Mid East Chapter, Nuclear Cardiology, Cardiac applications, myocardial imaging, dosimetry, theranostics, radiotracer bone scanning, lymphoma staging, PET applications for glioblastoma, thyroid cancer, prostate cancer, SPECT-CT, radiation safety, artificial intelligence, emerging radiopharmaceuticals, AI |
|